Phase 2 Study of aNK (Activated NK-92 Natural Killer Cells) Infusions in Combination With ALT-803 (IL-15) in Patients With Stage III (IIIB) or Stage IV Merkel Cell Carcinoma (MCC)

Trial Profile

Phase 2 Study of aNK (Activated NK-92 Natural Killer Cells) Infusions in Combination With ALT-803 (IL-15) in Patients With Stage III (IIIB) or Stage IV Merkel Cell Carcinoma (MCC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs CST 101 (Primary) ; ALT 803
  • Indications Merkel cell carcinoma
  • Focus Therapeutic Use
  • Sponsors NantKwest
  • Most Recent Events

    • 20 Mar 2017 According to a NantKwest media release, FDA has grant Orphan Drug Designation for company's activated natural killer (aNK) cell therapy for treatment of patients with advanced Merkel cell carcinoma was based in part on data presented at the Annual Society of Immunotherapy (SITC) meeting in November 2016.
    • 08 Mar 2017 Planned End Date changed from 1 Nov 2017 to 1 Dec 2017.
    • 08 Mar 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top